Literature DB >> 7330959

Pathological changes developing in the rat during a 3-week course of high dosage cyclosporin A and their reversal following drug withdrawal.

A W Thomson, P H Whiting, J T Blair, R J Davidson, J G Simpson.   

Abstract

Adult Sprague-Dawley rats given cyclosporin A (Cy A orally in a dose of 100 mg/kg/48 hr for 21 days displayed pronounced suppression of humoral immunity to sheep red blood cells. They showed hair loss and failure to gain weight and exhibited a progressive increase in serum urea, serum creatinine, and urinary N-acetyl-beta-D-glucosaminidase (NAG) activity, with a fall in urea clearance rate. Hypoalbuminemia and hyperbilirubinemia were observed in combination with a significant decrease in serum aspartate aminotransferase (AAT) and alkaline phosphatase levels. At 2 weeks, there was significant lymphopenia with the appearance of atypical lymphocytes in the peripheral blood. Autopsies performed on animals killed at 3 weeks revealed no light microscopic or ultrastructural differences between test and control animals, apart from some reduction in overall bone marrow cellularity in the former. During the 3-week period following withdrawal of Cy A, renal and hepatic function reverted to normal and a rebound lymphocytosis occurred. Only one of six rats autopsied 3 weeks after cessation of CY A administration showed reduced bone marrow cellularity. This study indicates that the rat may prove to be a useful experimental model for further investigation of te functional and structural changes which may be encountered in the clinical use of Cy A.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7330959     DOI: 10.1097/00007890-198110000-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  22 in total

1.  Effects of cyclosporin A on T-cell development in organ-cultured foetal thymus.

Authors:  Y Takeuchi; T Horiuchi; T Sugimoto; H Matsuda; H Yagita; K Okumura
Journal:  Immunology       Date:  1990-10       Impact factor: 7.397

2.  Comments on "cyclosporin does not affect the absolute rate of cortical bone resorption at the organ level in the growing rat".

Authors:  S Epstein; W S Jee; Y Ma; C C Liu
Journal:  Calcif Tissue Int       Date:  1995-06       Impact factor: 4.333

3.  Inhibition of contact sensitivity reactions to DNFB by topical cyclosporin application in the guinea-pig.

Authors:  R D Aldridge; A W Thomson; R Rankin; P H Whiting; C Cunningham; J G Simpson
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

4.  Renal function in rats treated with cyclosporin following unilateral nephrectomy.

Authors:  P H Whiting; J I Duncan; M P Gavin; S D Heys; J G Simpson; S K Asfar; A W Thomson
Journal:  Br J Exp Pathol       Date:  1985-10

5.  Experimental cyclosporin A nephrotoxicity.

Authors:  P H Whiting; A W Thomson; J T Blair; J G Simpson
Journal:  Br J Exp Pathol       Date:  1982-02

6.  Pathological changes in rats receiving cyclosporin A at immunotherapeutic dosage for 7 weeks.

Authors:  P H Whiting; J G Simpson; R J Davidson; A W Thomson
Journal:  Br J Exp Pathol       Date:  1983-08

7.  Cyclosporin A-induced nephrotoxicity in the rat: relationship to increased plasma renin activity.

Authors:  F T McAuley; J G Simpson; A W Thomson; P H Whiting
Journal:  Agents Actions       Date:  1987-06

8.  Effects of a selective adenosine A1 receptor antagonist on the development of cyclosporin nephrotoxicity.

Authors:  V S Balakrishnan; C J von Ruhland; D F Griffiths; G A Coles; J D Williams
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

9.  Renal injury induced by long-term administration of cyclosporin A to rats.

Authors:  T Bertani; N Perico; M Abbate; C Battaglia; G Remuzzi
Journal:  Am J Pathol       Date:  1987-06       Impact factor: 4.307

10.  Immunosuppressive activity and toxicity of cyclosporin A in rats pretreated with high dose cyclophosphamide.

Authors:  P A Brown; A W Thomson; P H Whiting; R J Davidson; J G Simpson
Journal:  Agents Actions       Date:  1985-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.